TYME and The Joseph Ahmed Foundation Announce First Patient Dosed in Phase II (HopES) Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with High-Risk Sarcomas

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Stacey Gandler
Brand Nourishment